Cue BiopharmaCUE
Market Cap: $27.7M
About: Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune disease with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103 and others.
Employees: 53
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
1,450% more call options, than puts
Call options by funds: $279K | Put options by funds: $18K
5% less funds holding
Funds holding: 77 [Q1] → 73 (-4) [Q2]
8.29% less ownership
Funds ownership: 36.66% [Q1] → 28.37% (-8.29%) [Q2]
17% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 23
32% less repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 22
45% less capital invested
Capital invested by funds: $31.3M [Q1] → $17.1M (-$14.2M) [Q2]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
3 analyst ratings
Stifel Stephen Willey 33% 1-year accuracy 5 / 15 met price target | 601%upside $4 | Buy Maintained | 20 Aug 2024 |
JMP Securities Reni Benjamin 41% 1-year accuracy 14 / 34 met price target | 251%upside $2 | Market Outperform Maintained | 26 Jul 2024 |
Piper Sandler Edward Tenthoff 35% 1-year accuracy 13 / 37 met price target | 426%upside $3 | Overweight Maintained | 26 Jul 2024 |
Financial journalist opinion
Based on 3 articles about CUE published over the past 30 days